- Home
- BKE vs GENB Comparison
BKE vs GENB Comparison
Compare BKE & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKE | GENB |
|---|---|---|
| Founded | 1948 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | BKE | GENB |
|---|---|---|
| Price | $42.61 | $13.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $53.00 | $23.20 |
| AVG Volume (30 Days) | 518.6K | ★ 829.1K |
| Earning Date | 05-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | ★ 6.43 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $1,297,835,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.99 | $16.58 |
| P/E Ratio | $45.64 | ★ N/A |
| Revenue Growth | ★ 6.58 | N/A |
| 52 Week Low | $40.73 | $11.00 |
| 52 Week High | $61.69 | $18.18 |
Technical Indicators
Market Signals| Indicator | BKE | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 40.20 |
| Support Level | $40.83 | $11.73 |
| Resistance Level | $43.82 | $13.76 |
| Average True Range (ATR) | 1.13 | 0.79 |
| MACD | 0.21 | -0.24 |
| Stochastic Oscillator | 50.71 | 5.08 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.